| Bioactivity | PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19[1]. | |||||||||
| Target | 3CLpro | |||||||||
| Name | PF-00835231 | |||||||||
| CAS | 870153-29-0 | |||||||||
| Formula | C24H32N4O6 | |||||||||
| Molar Mass | 472.53 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Robert L Hoffman, et al. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. J Med Chem. 2020 Nov 12;63(21):12725-12747. |
PF-00835231
CAS: 870153-29-0 F: C24H32N4O6 W: 472.53
PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and S
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.